ESCROW AGREEMENT FOR SECURITIES OFFERINGEscrow Agreement • August 2nd, 2022 • Oncolyze, Inc. • Pharmaceutical preparations • Delaware
THIS ESCROW AGREEMENT, dated as of 7/15/2022(“Escrow Agreement”), is by and between SI Securities, LLC (“SI Securities”), Oncolyze, Inc, a Delaware corporation
SUBSCRIPTION AGREEMENTSubscription Agreement • August 2nd, 2022 • Oncolyze, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
Oncolyze, Inc. Dr. Alex Stojanovic 36 Fountayne Lane Lawrenceville, NJ, 08648 Dear Alex:Oncolyze, Inc. • August 2nd, 2022 • Pharmaceutical preparations • New York
It is our pleasure as the Board of Directors of Oncolyze, Inc. (the “Board”) to offer you a contract for the position of Chief Operations Officer (“COO”) of Oncolyze, Inc. (or any successor or parent, the “Company”). This letter, including Exhibit A, sets forth the terms of understanding for your employment (“Agreement”). The date this letter is signed by both you and the Company shall be referred to as the“Execution Date”.
EMPLOYMENT AGREEMENTEmployment Agreement • August 2nd, 2022 • Oncolyze, Inc. • Pharmaceutical preparations • New York
This employment Agreement (the “Agreement”), effective February 28 2019, or such earlier date as may be agreed by the parties (the “Effective Date”), is made and entered into by and between Oncolyze, Inc. (the “Company”), and Larry Altstiel, M.D., Ph.D. (the “Executive”).
CONSULTING AGREEMENTConsulting Agreement • August 2nd, 2022 • Oncolyze, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”) is made effective as of June 9, 2021 (the “Effective Date”), by and between Oncolyze, Inc., a Delaware corporation, with its principal place of business being 815 United Nations Plaza, Apt 61b, New York, New York 10017 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
